Cavitary bone defects are created in the curettage or debridement of benign bone tumors, infections, or low-grade malignancies. In order for new bone to fill these defects, the material that resides within must be osteoconductive, or an appropriate scaffolding that prevents non-osseous (fibrous) tissue infiltration, supports the attachment of new osteoblasts and osteoprogenitor cells, and sustains an interconnected structure through which new cells can migrate and new vessels can form.
associated with bone allografting to be one in 1.6 million; 13 there have, however, been no documented instances of HIV or HCV transmission through irradiated bone. 14 In response to the disadvantages of autograft and allograft, synthetic bone graft substitutes have evolved. Four classes of synthetic bone graft substitute exist:
• allograft-based-allograft bone used in combination with other bone substances: demineralized bone matrix (DBM);
• factor-based-natural/recombinant growth factors of bones:
transforming growth factor beta (TGF-β), platelet-derived growth factor (PDGF), fibroblast growth factor, and bone morphogenetic protein (BMP);
• polymer-based-degradable and non-degradable polymers of bone:
polylactic acid and polyglycolic acid; and
• ceramic-based: calcium sulfate, calcium phosphate, and bioglass.
The ceramic-based class accounts for over 60% of the synthetic market, a vast majority of which consists of mineral-based ceramics, which are the focus of this article. The purpose of this article is to review the published literature on the use of mineral bone graft substitutes in the grafting of bone defects created in the treatment of benign bone tumors in order to describe their risks, benefits, differences, and outcomes individually and in comparison with each other.
Materials and Methods
A complete Medline search was conducted for all articles describing mineral bone graft substitutes in the treatment of surgically created cavitary bone defects, specifically looking for recent high-level comparative studies but also including review and instructional articles.
All of these studies were subsequently further cross-referenced among their citations to retrieve all relevant literature. Relevant pre-clinical studies on the use of mineral bone graft substitutes were also included. Studies involving bone grafting of spinal fusion, trauma, sports, and joint reconstruction procedures were generally excluded, with the exception of high-level or comparative studies that may apply to the treatment of surgically created cavitary bone defects.
General Review of Mineral-based Ceramics
Ceramic bone graft substitutes have been shown to be osteoconductive, virtually unlimited in supply, uniform in quality, without donor site morbidity, and without risk of disease transmission. [15] [16] [17] [18] The downsides of ceramics include their brittleness, low tensile strength, potential antigenic reactions, lack of osteoinductive and osteogenic properties, high cost (up to $400/cc, resulting in $150million in costs each year in the US), variable resorption rates, and potential for interference with wound healing. 2, 4, 5, 15, 16 Indications for the use of a mineral bone graft substitute include a surgically or traumatically created bone defect that requires grafting for optimal consolidation. Relative contraindications include active infection, high infection risk, open fracture, lack of soft-tissue coverage, and bovine sensitivity (when collagen composite products are used).
Numerous in vitro and in vivo studies have demonstrated the osteoconductivity of mineral bone graft substitutes. 4, 5, 15, 16 The pore size of the synthetic bone graft that allows for optimal scaffolding provision, osteoconductivity, and subsequent bone ingrowth and resorption is 150-500µ, which falls into the range of most synthetic mineral grafts available. 4 The most notable clinical difference between different mineral bone graft substitute compounds is their varying rates of resorption: smaller particulate grafts are resorbed by osteoclasts and more expediently, while larger particulate grafts are resorbed by foreign body giant cells in a much slower manner. 17 The different mineral bone graft compounds have very different biochemical characteristics; therefore, the detailed biology and clinical results of each class are described individually.
Calcium Sulfates
The original mineral bone graft substitute, calcium sulfate (CaSO 4 ), dates back to 1892 in its use as a bone graft for cavitary defects. 19 The compound is derived by adding water to calcium sulfate hemihydrate. This creates gypsum, which is subsequently heated, leading to its crystallization as calcium sulfate. 5, 20 In literature from the distant past, Peltier and others state that calcium sulfate is biocompatible, bioabsorbable, radio-opaque, safe, non-immunogenic, non-osteoinhibitive, and regular in its resorption, and there is no infection from sequestration. These early studies also indicate, however, that calcium sulfate needs bone or periosteum for new bone to be incorporated. 3 Calcium sulfate creates an acidic environment in vivo (calcium phosphate and sulfuric acid) that may be toxic to bacteria. For this reason, it has long been used as a treatment for osteomyelitis, with or without an associated antibiotic. 21, 22 In the earliest series involving humans, Peltier and Jones reviewed 26 unicameral bone cysts (UBCs) treated with curettage followed by packing with calcium sulfate pellets (plaster of Paris). They noted uneventful healing in all except for two patients (7.7%), who developed serous drainage that required revision surgery. 21 In more recent years, significant data regarding calcium sulfate has come from animal studies. Calcium sulfate has been shown to adhere to osteoblasts and osteoclasts in vitro and to be resorbed by osteoclasts in rats. 23 At 12 weeks, a study of sheep femur defects found BMP-2, BMP-7, TGF-β, and PDGF staining to be highest in the femurs grafted with calcium sulfate plus autograft, followed by calcium sulfate alone, followed by autograft, followed by nothing at all. 24 In a canine model, the paper's authors demonstrated that calcium sulfate appeared to be completely resorbed and replaced by bone at 13 weeks, with no adverse inflammatory response. 25 The same authors also described a series of four different canine models in a single article. 26 In their canine spine-fusion model, calcium sulfate had a significantly smaller area of bone fusion mass compared with autograft alone and was similar to no graft at all. After implantation of 10% tobramycin-impregnated calcium sulfate, local concentrations of antibiotic dropped to undetectable levels by 28 days, systemic concentrations were undetectable within 24 hours in a dose-dependant manner, and there was no local or systemic toxicity. Calcium sulfate resorbed completely and was shown to be osteoconductive in the canine humerus. Calcium sulfate with DBM had significantly more new bone formation at six weeks compared with calcium sulfate alone. 26, 27 Another canine bilateral defect model was used to compare a stronger calcium sulfate (MIIG X-3) versus conventional calcium sulfate pellets (Osteoset), and found a three-fold increase in initial compressive strength in MIIG group.
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Many of the clinical studies using calcium sulfate in the treatment of bone defects are retrospective in nature and many come from the trauma literature (see Table 1 ). In a review of 26 patients with a non-union (19) Musculoskeletal Cancer Of all studies regarding the use of calcium sulfate in benign bone defects, only two high-level clinical studies (level I/II) have been performed. 41 Kelly et al. conducted a level II prospective, multicenter cohort study of Osteoset pellets in 109 patients requiring a morcelized bone graft for a non-structural bone defect from multiple conditions in multiple locations (including a 46-patient subgroup of benign bone tumors). Of these, 65% had adjuvant graft (DBM, bone marrow aspirate, cancellous allograft, or cancellous autograft). 42 Looking at calcium sulfate alone, there was 99% resorption and 98% new bone formation at 12 months. In the bone tumor subset treated with Osteoset alone (10 patients), there was 100% graft resorption and 97% new bone formation at 12 months. There was a 12% complication rate, including three infections (2.8%), two pathologic fractures (1.8%), and four cases of serous drainage that resolved once the pellets were absorbed (3.6%). An elegant level 1 prospective randomized, double-blind, controlled study compared calcium sulfate versus no grafting at all in tibial bone defects created after bone-patellar-tendon-bone harvest for knee ligament surgery. The authors studied the amount of new bone formation with serial computed tomography (CT) scans at 0, 6, 12, and 24 weeks. 43 Significantly increased new bone was found in both groups from zero to six weeks and significantly increased bone was observed in the control group alone from six to 12 weeks compared with Osteoset (p=0.01).
However, no statistical difference was found between the two groups at any time interval.
Calcium Phosphates

Hydroxyapatite
In response to the rapid absorption and inflammation associated with calcium sulfate, calcium phosphate compounds with potentially improved biological and mechanical properties gained popularity. Several pre-clinical studies have evaluated the initial safety and efficacy of HA as a bone void filler. In their implantation of 52 canine bone defects from various sites with HA, the authors of one study found the construct to be weak initially, but to be almost as strong as native bone upon incorporation. 45 Another canine model found the HA graft site to consist of 52% soft tissue, 13% new bone, and 35% HA at 12 months, with 67% of the HA surface being covered with new bone. 46 In a canine humeral defect model, at 16 weeks 50-60% of pores were filled with new bone and compressive strength was two to three times that of the surrounding cancellous bone; however, the grafted area only reached cortical bone strength, and the bending strength of the associated cortical bone returned to only 10% of its normal value. 47 Shors and Holmes looked at 37 biopsy specimens of HA implants taken a mean 14 months post-grafting through light microscopy and electron scanning microscopy. They found 30% soft tissue, 31% HA, and 38% new bone, with 56% of the implant surfaces being covered by bone. 48 All of the clinical studies using HA grafting in the treatment of bone tumors are retrospective in nature (see Table 2 ). One study looked at 23 patients in whom simple bone cysts were treated by curettage followed by HA cube packing. It found complete healing without cyst recurrence in 78% of cases at two years, with new bone surrounding the HA at an average of 2.3 months. 49 Two Indian studies of bovine HA studied grafting after benign bone tumor treatment in a small number of cases (12 and 23) and followed them clinically and radiographically for up to six years.
The authors found the graft material to be biocompatible, safe, and slow to remodel, with no adverse effects or graft-related complications.
50,51
Uchida et al. reported on 60 cases in which HA bone graft was used to fill resected benign bone tumors. Patients were followed up for a mean of 36 months. 52 The authors biopsied seven specimens (cases requiring surgery for other reasons) and found new bone ingrowth onto the graft in all cases. They did, however, experience three (5%) pathologic fractures and saw minimal radiographic resorption in all cases, even at five years. Another study looked retrospectively at 51 patients with As with calcium sulfate, the highest-level studies involving the use of HA in bone defects come from the trauma literature (see Table 3 ). In 1989, Bucholz et al. in a prospective, randomized study compared operative tibial plateau fractures treated with HA (Pro Osteon) grafting against those treated with iliac crest cancellous autograft. 55 They followed autograft patients for 15.4 months and HA patients for 34.5 months and were unable to find any statistical differences in maintenance of reduction, union rates, or complications. In seven HA cases requiring further surgery, biopsy was performed and revealed 25-47% new bone ingrowth and 25-39% residual HA. They also found a lack of radiographic HA resorption in all cases at follow-up. Another prospective, randomized, multicenter study looked at HA cement (BoneSource) compared with iliac crest bone graft in the treatment of traumatic metaphyseal defects throughout the skeleton. The authors found that maintenance of reduction and 'success' increased in the HA group compared with the iliac crest bone graft group at six (69 versus 57%) and 12 months (79 versus 70%), as did maintenance of reduction (83 versus 67%), but these differences did not achieve statistical significance. 56 
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U S O N C O L O G Y & H E M A T O L O G Y
Tricalcium Phosphates
In response to the delayed resorption profiles of HA, the tricalcium phosphate (TCP: Ca 3 (PO 4 ) 2 ) group evolved. This group is also in the calcium phosphate family, which includes alpha, beta, and gamma subtypes. Alpha-TCP (α-TCP) is polygonal in structure while β-TCP is spherical, more porous, and more trabeculated, and resorbs faster than α-TCP. 63 In a canine study of 1cm tibial defect treated with grafting and external fixation, a combination TCP (36% alpha and 64% beta; Cellplex) showed statistically increased torsional strength and stiffness compared with autograft, allograft, and no graft at six weeks but not at eight weeks. There was complete histologic bone ingrowth, with 38% residual implant, at eight weeks. 64 In a study of 40 patients with bone defects (including eight benign bone tumors), the authors found excellent results with the use of β-TCP;
however, this may last a variable number of years without being resorbed. 65 Another study of 18 pediatric bone cysts treated with TCP also found two recurrences, with the remaining 16 patients having well-incorporated grafts with no adverse reaction. They did, however, find residual TCP up to seven years post-operatively. 66 proportional to the size of the defect. 69 Other investigators have found that the size and volume of the defect and graft, as well as the patient's age and bone quality, are important factors affecting the integration of β-TCP into host bone. 70 In a level III retrospective study comparing HA (Bonfil) with β-TCP (OSferion) in 53 patients with benign bone tumors, both groups had two pathologic fractures (7.6% overall). The authors found β-TCP to be a more attractive bone graft substitute since it showed evidence of graft resorption and new bone formation in all cases. One patient with subchondral giant cell tumor treated with HA graft sustained varus deformity requiring surgical revision. 71 While most TCP ceramics are made through a high-pressure sintering technique with compaction, new proprietary formation techniques have been developed that may make these implants more biochemically favorable. 4 One such proprietary technique of β-TCP machining creates an ultraporous β-TCP (Vitoss) that has been the subject of several studies. Vitoss consists of 75% 100-1,000µ pores for bone ingrowth and 25% smaller (<100µ) pores, theoretically aiding in diffusion. 4, 44 In a review of six cases where Vitoss was used in human fractures, no adverse reactions were seen. One case of biopsy nine months post-operatively showed new bone formation, no inflammatory reaction, and 'significant quantities of the graft remaining. 72 In a retrospective radiographic case series, 60 patients with cavitary bone defects were treated with Vitoss.
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Bone marrow aspirate and resorption were determined on X-ray. 73 The geometry that also allows for increased scaffolding, implantation of cells and factors, and bone ingrowth. 5 In an interesting canine humerus defect model, FormPutty, Vitoss, autograft, and no graft at all were compared head to head histopathologically and mechanically. 75 4, 5 These substances set in less than 10 minutes and achieve maximal compressive strength at 24 hours. One study showed that its calcium phosphate cement had an initial set time of 2.75 minutes, a final set time of 7.5 minutes at 37ºC, and a final compressive strength of 48MPa at 24 hours (the maximum compression strength of cancellous bone is 30MPa). 77 A study of the calcium phosphate cement
Norian SRS showed a final compressive strength of 55MPa at 24 hours. 78 This graft and surrounding bone remodels over time. It is absorbed by osteoclasts, results in new lamellar bone formation, and resorbs slowly, with 30-60% resorbed at one year. 79 Most of the calcium phosphate cements cure in an isothermic manner; however, some may be slightly exothermic (e.g. Mimix), albeit not enough to cause the thermal tissue damage seen with polymethylmethacrylate. 79 A human cadaveric lateral tibial plateau fracture model comparing cancellous grafting with α-BSM calcium phosphate bone cement found statistically increased stiffness and resistance to displacement (p<0.0001) in the α-BSM group. 80 Progressing from these pre-clinical studies, numerous level I studies have prospectively looked at calcium phosphate cement (Norian and α-BSM) in the supportive treatment of metaphyseal fractures (see Table   3 ). These studies have found statistically improved early motion in distal 
Mineral Bone Graft Composites
In the quest to improve the delivery vehicle of bone graft substitutes in order to avoid problems-including difficult handling, inability to fully fill the void, extravasation into soft tissues, and the desire to obtain further biological advantage-collagen-and silicon-based composites were developed. Modifications of the TCP include the formulation packing, strip, or moldable putty vehicles that usually involve the addition of a matrix substance such as type I bovine collagen (i.e. Vitoss Scaffold Foam).
The addition of type I collagen decreases compressive strength and the collagen portions are quickly absorbed. 5 These composites cannot be used in patients with allergies to bovine collagen. In a level I prospective, randomized, multicenter study, 297 long-bone fractures from various sites that required surgical stabilization were grafted with 65% HA/35%
TCP plus type I bovine collagen (Collagraft) or iliac crest autograft. The authors were unable to find differences in union (88% power) or function between the groups. Twelve patients developed bovine collagen antibodies, but no related problems occurred. 93 With regard to silicated mineral compounds, no studies have been performed to evaluate their safety and efficacy in human bone defects.
In vitro biochemical studies have produced mixed results, with some claiming improved biological activity with silication by increasing the solubility of the material, creating a more electronegative surface, and developing a finer microstructure. 94 A conflicting bench study states that "there is no experimental evidence that Si ions are released from Si-substituted calcium phosphates at therapeutic concentrations, and there is no study linking the improved biological performance of Si-substituted calcium phosphates to Si release." 95 In an elegant animal histological study, the authors compared calcium sulfate (Osteoset), In order to obtain the optimal chemical and biological characteristics of the available mineral compounds (i.e. resorption profiles), mixtures of the mineral compounds themselves were developed. In a canine study of diaphyseal fracture defects filled with a granular HA/TCP ceramic, the authors concluded the graft was biocompatible and osteoconductive but not osteoinductive or osteogenic, being unable to promote healing in large fracture defects. 99 
Discussion
Only one level III study, 71 two level II studies, 42, 103 increased growth factor staining in calcium sulfate grafts compared with no graft at all, but did not demonstrate any correlation of this staining to new bone formation. 24 One canine study of a diaphyseal tibial defect found increased strength and stiffness in the β-TCP grafted group compared with no graft at six weeks, but no differences were found at eight weeks. 64 Another canine study comparing two commercially available β-TCP products was unable to find statistical differences in either graft compared with no graft at all in terms of new bone formation, yield force, stiffness, or failure force at any time interval. In addition to biology, the other potential benefit of bone grafting may come from increased mechanical strength. None of the older blocks or granules can achieve compressive strength any greater than that of cancellous bone, but calcium phosphate cements have been able to exceed it. The strength of these calcium phosphate cements is only in compression, however, and this compressive strength is still nowhere near that of cortical bone. The cements still remain weak in shear, tension, torsion, and bending. Most pathologic fractures from bone defects occur during torsional or bending moments over cortical bone defects. 1 In this regard, grafting with blocks, granules, or cements does little to prevent pathologic fracture, as evidenced by a post-operative pathologic fracture incidence of up to 7.7% seen in a number of series. 
